Researchers Find DMT Provides Longer-Lasting Antidepressant Effects than S-Ketamine in Animal Models

Why It Matters

DMT’s prolonged antidepressant and anxiolytic profile could offer a faster, longer‑lasting alternative to ketamine for treatment‑resistant depression, reshaping rapid‑acting therapeutic strategies.

Key Takeaways

• Single DMT dose reduced despair for up to eight days in mice
• DMT alleviated anhedonia for five days, matching S‑ketamine
• Only DMT increased open‑arm exploration, indicating anxiolytic effect
• Effects required group housing; isolated mice showed limited immediate recovery
• Study used male Swiss mice; female response remains untested

Pulse Analysis

The search for fast‑acting antidepressants has accelerated since ketamine demonstrated rapid relief for treatment‑resistant depression. S‑ketamine, approved as a nasal spray, shortens the latency to symptom improvement but carries concerns about dissociation, abuse potential, and a limited duration of effect. In parallel, serotonergic psychedelics such as N,N‑dimethyltryptamine (DMT) have re‑emerged as candidates that may trigger profound neuroplastic changes after a single administration. Early human trials suggest DMT can lift depressive symptoms, yet rigorous preclinical comparisons with established agents have been scarce. Moreover, the rapid onset aligns with the clinical need for emergency interventions.

The Neuropharmacology study addressed that gap by administering a single intraperitoneal dose of DMT (10 mg/kg or 25 mg/kg) to male Swiss mice subjected to learned‑helplessness, a validated model of depression. Both DMT and S‑ketamine reversed despair behavior within 24 hours, but only DMT sustained tail‑suspension resilience for eight days and restored sucrose preference for five days. Moreover, DMT uniquely increased open‑arm time in the elevated plus‑maze, indicating anxiolytic activity absent in S‑ketamine. Notably, these benefits were evident in group‑housed mice, whereas isolated animals showed limited immediate escape recovery. The dose‑response pattern also suggested that lower DMT concentrations were sufficient for sustained benefit.

These findings position DMT as a potentially longer‑lasting, dual‑action antidepressant‑anxiolytic compared with current rapid‑acting options. If similar durability translates to humans, clinicians could reduce dosing frequency and mitigate side‑effects associated with repeated ketamine infusions. However, the study’s reliance on male rodents, the absence of head‑twitch data, and the controlled laboratory setting temper enthusiasm. Future work must explore sex differences, delineate serotonin‑receptor mechanisms, and conduct safety‑focused clinical trials before DMT can move from bench to bedside as a regulated therapy for severe mood disorders. Regulatory pathways will likely require robust biomarker data to demonstrate lasting neuroplastic changes.